Clinical Social Workers in Wiloughby, OH Accepting Medicare
1 Clinical Social Workers found. Showing 1 - 1
 Mrs. Peggy Sue Mcknight, L.I.S.W. Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 4212 Ohio State Route 306, Suite 100, Wiloughby, OH 44094 Phone: 216-831-6611 Fax: 216-456-8128 |
News Archive
Genetic test to identify women at higher risk of breast cancer could reduce risks associated with screening
Calculating individual genetic cancer risk and taking age into account could mean fewer women would need to be screened for breast cancer, according to research published in the British Journal of Cancer1.
Avoiding expensive colleges can lead to bigger financial problems in the long run, study suggests
Choosing more expensive colleges may seem like an unwise financial decision considering a large student debt burden after graduation. However, new research led by the Indiana University Kelley School of Business demonstrates that avoiding such colleges can lead to bigger financial problems in the long run.
Penn Medicine receives federal government approval to develop imaging guidelines
The United States Congressional Budget Office estimates that 5 percent of the country's gross domestic product is spent on medical tests and procedures that do not improve patient outcomes.
Self-powered bandage generates electricity, reduces healing time for skin wounds in rats
Skin has a remarkable ability to heal itself. But in some cases, wounds heal very slowly or not at all, putting a person at risk for chronic pain, infection and scarring. Now, researchers have developed a self-powered bandage that generates an electric field over an injury, dramatically reducing the healing time for skin wounds in rats.
Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.
› Verified 6 days ago